 MARLBOROUGH, Mass., June 4, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today announced positive in vivo data that provide further evidence on the utility of its INTASYLTM self-delivering RNAi therapy platform in the field of immuno-oncology. 